Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedPage revision shows Revision: v3.3.2 added and Revision: v3.3.1 removed, indicating a minor platform update. This change does not affect the study details, eligibility criteria, outcomes, or navigation on the page.SummaryDifference0.0%

- Check25 days agoChange DetectedPublications section updated to indicate entries are automatically filled from PubMed and to display revision: v3.3.1. The previous PubMed wording and the older revision label v3.2.0 were removed.SummaryDifference0.0%

- Check32 days agoChange DetectedTwo new trial locations were added in Tainan, Taiwan (postal codes 00704 and 710). The previous entries listed as 'Tainan City, Taiwan' for those postcodes were removed.SummaryDifference0.2%

- Check46 days agoChange DetectedBoth screenshots show the same study details with no changes to core information such as title, conditions, interventions, eligibility criteria, enrollment numbers, or primary outcomes; only minor formatting adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check75 days agoChange DetectedMajor updates: added government operating status notice and new research citation; updated version to v3.2.0, replacing the previous v3.0.2.SummaryDifference2%

- Check76 days agoChange DetectedPage version updated to v3.1.0 and a new 2025 citation added; previous version v3.0.2 removed.SummaryDifference0.6%

Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.